MABVAX THERAPEUTICS HOLDINGS, INC. (MBVX) News Headlines

▮ More

Date

Headline

10/31/2017 7:41:58 AM MabVax Therapeutics Provides Important Update On Its HuMab-5B1 Clinical Program

10/12/2017 1:15:08 AM ARDX Surges After-hours, MBVX Abuzz, TRVN Keeps Its Focus

10/11/2017 8:03:05 AM MabVax Therapeutics Initiates Patient Enrollment In A Phase 1 Trial For MVT-1075

8/23/2017 2:01:56 AM RARE Disappoints, NSPR Put On Notice, PMD Launches Synthetic Cannabinoids Test

8/14/2017 8:12:53 AM MabVax Reports Sale Of $1.31 Mln Of Shares Of Series J Convertible Preferred Stock

6/27/2017 8:07:51 AM MabVax Commences Dosing In MVT-1075 Radioimmunotherapy Phase 1 Trial For Treatment Of Pancreatic, Colon And Lung Cancers

6/14/2017 7:05:47 AM MabVax Therapeutics Reports Positive Phase 1 Results For MVT-2163 ImmunoPET Imaging Agent

6/7/2017 7:06:21 AM MabVax Therapeutics ImmunoPET Imaging Agent MVT-2163 To Be Featured In Two Presentations At 2017 SNMMI Annual Meeting

6/5/2017 7:09:51 AM MabVax Presents Phase I Trial Results Of Antibody Therapy MVT-5873 For Treatment Of Advanced Pancreatic Cancer At ASCO

5/31/2017 7:07:38 AM MabVax Therapeutics Signs Deal With MSK Cancer Center To Develop Novel CAR T-Cell Based Anti-Cancer Immunotherapies

5/24/2017 7:06:30 AM MabVax Therapeutics Q1 Net Loss $5.4 Mln Or $0.85/shr Vs Loss Of $4.4 Mln Or $1.12/Shr Last Year

5/22/2017 7:03:23 AM MabVax Therapeutics Announces Closing Of $4.1 Mln Public Offering Of Common Stock And Series G Preferred Stock

5/16/2017 2:54:30 AM AKBA Abuzz, ANTH On Track For RESULT, IMUC Faces Cash Crunch, IONS Falls

2/23/2017 8:34:38 AM MabVax Says FDA Authorization To Proceed With MVT-1075 In Phase I Trial For The Treatment Of Pancreatic Cancer

1/9/2017 8:19:27 AM MabVax Therapeutics Files INDA For Novel Radioimmunotherapy Agent MVT-1075

12/5/2016 8:14:09 AM MabVax Expands Phase I Trial Investigation For Patients With Pancreatic Cancer To Include HonorHealth Research

11/28/2016 8:10:48 AM MabVax Therapeutics Enrolls First Patients In Expansion Of Phase I Clinical Trial

11/14/2016 9:08:48 AM MabVax Reports Safety And Imaging Results From Phase I Clinical Trials In HuMab-5B1 Antibody Development Programs

11/10/2016 8:27:39 AM MabVax Therapeutics Q3 Net Loss Attributable To Stockholders $4.36 Mln Or $0.86 Per Share

9/26/2016 9:10:17 AM MabVax Therapeutics HuMab-5B1 Based Diagnostic Imaging And Radioimmunotherapy Programs Featured

Mabvax Therapeutics Holdings, Inc. (MBVX)